Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
9848544
Reference Type
Journal Article
Title
Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas
Author(s)
Dvorakova, S; Vaclavikova, E; Sykorova, V; Vcelak, J; Novak, Z; Duskova, J; Ryska, A; Laco, J; Cap, J; Kodetova, D; Kodet, R; Krskova, L; Vlcek, P; Astl, J; Vesely, D; Bendlova, B
Year
2008
Is Peer Reviewed?
1
Journal
Molecular and Cellular Endocrinology
ISSN:
0303-7207
EISSN:
1872-8057
Volume
284
Issue
1-2
Page Numbers
21-27
Language
English
PMID
18282654
DOI
10.1016/j.mce.2007.12.016
Abstract
The frequency and prognostic relevance of RET proto-oncogene somatic mutations in sporadic medullary thyroid carcinoma (MTC) remain controversial. In order to study somatic mutations in the RET proto-oncogene in sporadic MTCs found in the Czech population and to correlate these mutations with clinical and pathological characteristics, we investigated 48 truly sporadic MTCs by sequencing classical risk exons 10, 11, 13, 14, 15 and 16. From the 48 tumors studied, 23 (48%) had somatic mutation in the RET proto-oncogene in exons 10, 11, 15 or 16. The classical somatic mutation Met918Thr in exon 16 was only found in 13 tumors (27%). In five cases, multiple somatic mutations and deletions were detected. A statistically significant correlation between the presence of somatic mutation with more advanced pathological TNM stages was observed. Other clinical and pathological characteristics did not show any statistical significant association with the presence or absence of somatic mutation.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity